A share price of X4 Pharmaceuticals Inc [XFOR] is currently trading at $2.13, up 17.03%. An important factor to consider is whether the stock is rising or falling in short-term value. The XFOR shares have gain 39.22% over the last week, with a monthly amount glided 6.50%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
X4 Pharmaceuticals Inc [NASDAQ: XFOR] stock has seen the most recent analyst activity on December 12, 2023, when B. Riley Securities downgraded its rating to a Neutral and also revised its price target to $1 from $3. On December 22, 2022, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $3 on the stock. Piper Sandler started tracking the stock assigning a Overweight rating and suggested a price target of $3 on December 12, 2022. Oppenheimer initiated its recommendation with a Outperform and recommended $20 as its price target on December 23, 2019. ROTH Capital started tracking with a Buy rating for this stock on December 18, 2019, and assigned it a price target of $20. In a note dated December 09, 2019, Citigroup upgraded an Buy rating on this stock and boosted its target price from $16 to $20.
X4 Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $1.38 and $26.83. Currently, Wall Street analysts expect the stock to reach $3.67 within the next 12 months. X4 Pharmaceuticals Inc [NASDAQ: XFOR] shares were valued at $2.13 at the most recent close of the market. An investor can expect a potential return of 72.3% based on the average XFOR price forecast.
Analyzing the XFOR fundamentals
Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at -0.27%, Pretax Profit Margin comes in at 0.48%, and Net Profit Margin reading is 0.47%. To continue investigating profitability, this company’s Return on Assets is posted at 0.11, Equity is 0.29 and Total Capital is -0.08. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.9200 points at the first support level, and at 1.7100 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.2800, and for the 2nd resistance point, it is at 2.4300.
Ratios To Look Out For
To put it in perspective, the Current Ratio for X4 Pharmaceuticals Inc [NASDAQ:XFOR] is 3.70. On the other hand, the Quick Ratio is 3.58, and the Cash Ratio is 1.56. Considering the valuation of this stock, the price to sales ratio is 0.39, the price to book ratio is 0.54 and price to earnings (TTM) ratio is 0.95.
Transactions by insiders
Recent insider trading involved Baldry Mark, Chief Commercial Officer, that happened on May 16 ’25 when 1032.0 shares were purchased. Chief Commercial Officer, Baldry Mark completed a deal on Nov 15 ’24 to buy 13404.0 shares. Meanwhile, President and CEO Ragan Paula sold 76473.0 shares on Jan 24 ’25.
